HLS Therapeutics Inc.
HLTRF
Other OTC3.00
USD
- -
- -
ISIN
CA40390B1094
CUSIP
40390B109
Return %
Stock
S&P500
1Y
-18.03
20.98
3Y
-35.90
70.79
5Y
-78.57
73.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Craig Stuart Millian
- Full Time Employees
- 92
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 10 Carlson Court Etobicoke ON Canada M9W 6L2
- IPO Date
- Jan 27, 2010
- Website
- hlstherapeutics.com
- Similar Companies
- Business
- HLS Therapeutics Inc is a specialty pharmaceutical company focused on the acquisition and commercialization of branded pharmaceutical products primarily in the North American markets, including Canada and the United States. Its core product portfolio consists of Clozaril, an atypical antipsychotic indicated for treatment-resistant schizophrenia; Vascepa, icosapent ethyl capsules prescribed for cardiovascular risk reduction; and CSAN Pronto, a capillary point-of-care medical device designed to simplify mandatory safety blood monitoring for patients on Clozaril. The company operates in central nervous system (psychiatric disorders) and cardiovascular therapeutic areas, delivering products that meet stringent FDA and Health Canada regulatory requirements. Founded in 2002 and headquartered in Toronto, Canada, HLS maintains operations in the Toronto, Montreal, and Philadelphia metropolitan areas. In recent years, HLS Therapeutics has undergone significant strategic changes including the streamlining of its operating model and strengthening of its balance sheet with substantial debt repayments to improve financial flexibility and future profitability prospects. In 2024, the company transitioned its go-to-market model for Vascepa from Pfizer back to internal management to enhance return on investment after evaluating sales performance. HLS has emphasized growth in its promoted product portfolio while reducing operating expenses to position itself for top-line growth and increased profitability moving into 2025. The company also continues to enhance its CSAN Pronto device to improve safety monitoring for Clozaril patients and pursues portfolio expansion initiatives to fuel long-term growth. HLS Therapeutics serves healthcare providers and patients by ensuring reliable market access to trusted branded medicines in its specialty CNS and cardiovascular niches. It generates revenue primarily through product sales augmented by royalties. The company’s strategic focus is on addressing unmet medical needs with clinically differentiated therapies, leveraging partnerships and in-licensing to expand its commercial offerings. With a relatively lean workforce of approximately 90 employees, HLS Therapeutics aims to consolidate its leadership in specialty pharmaceutical acquisitions and commercialization across North America while actively managing operational efficiencies and product demand growth strategies.
HLS Therapeutics Q1 Earnings Call Highlights
HLS Therapeutics Inc. (HLS:CA) Q4 2025 Earnings Call Transcript